Syncope disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SYN036 MIFTS: 45	Syncope
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Syncope

MalaCards integrated aliases for Syncope:

Name: Syncope ⁵³ ²⁹ ⁶

Sources

Summaries for Syncope

NINDS : ⁵³ Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.” The skin may be cold and clammy. The person drops to the floor as he or she loses consciousness. After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal. Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly. There are several types of syncope. Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing. Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar. Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation. Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body. Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy. Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Syncope is related to atrial standstill and left bundle branch hemiblock. An important gene associated with Syncope is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and cGMP-PKG signaling pathway. The drugs Dopamine and Fludrocortisone have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and brain, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : ⁷⁴ Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Sources

Related Diseases for Syncope

Diseases related to Syncope via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)

#	Related Disease	Score	Top Affiliating Genes
1	atrial standstill	10.2	SCN5A NPPA
2	left bundle branch hemiblock	10.1	SCN5A RYR2
3	arrhythmogenic right ventricular dysplasia, familial, 12	10.1	RYR2 KCNH2
4	right bundle branch block	10.1	SCN5A KCNH2
5	cardiomyopathy, dilated, 1b	10.1	TTN SCN5A
6	long qt syndrome 12	10.1	SCN5A KCNQ1 KCNH2
7	long qt syndrome 10	10.1	SCN5A KCNQ1 KCNH2
8	supravalvular aortic stenosis	10.1	SCN5A KCNH2
9	familial isolated arrhythmogenic ventricular dysplasia, left dominant form	10.0	TTN RYR2
10	familial isolated arrhythmogenic ventricular dysplasia, biventricular form	10.0	TTN RYR2
11	long qt syndrome 11	10.0	KCNQ1 KCNJ2
12	familial isolated arrhythmogenic ventricular dysplasia, right dominant form	10.0	TTN RYR2
13	cardiomyopathy, dilated, 1dd	10.0	TTN RYR2
14	peripartum cardiomyopathy	10.0	TTN SCN5A
15	familial periodic paralysis	10.0	SCN5A KCNJ2
16	arrhythmogenic right ventricular dysplasia, familial, 1	10.0	TTN RYR2
17	hyperkalemic periodic paralysis	10.0	SCN5A KCNJ2
18	brugada syndrome 1	10.0	SCN5A RYR2 KCNH2
19	progressive familial heart block	9.9	SCN5A KCNQ1
20	ventricular tachycardia, catecholaminergic polymorphic, 3	9.9	RYR2 KCNJ2
21	congenital structural myopathy	9.9	TTN RYR2
22	dopamine beta-hydroxylase deficiency	9.9	SLC6A2 DBH
23	familial isolated dilated cardiomyopathy	9.9	TTN SCN5A ACTN2
24	long qt syndrome 9	9.8	SCN5A KCNQ1 KCNJ2
25	familial short qt syndrome	9.8	KCNQ1 KCNJ2 KCNH2
26	oppositional defiant disorder	9.8	SLC6A2 DBH
27	diastolic heart failure	9.8	TTN NPPA
28	atrial heart septal defect	9.8	TTN SCN5A NPPA
29	cardiac conduction defect	9.8	SCN5A RYR2 KCNQ1 KCNH2
30	ventricular fibrillation, paroxysmal familial, 1	9.8	SCN5A RYR2 KCNQ1 KCNH2
31	sudden infant death syndrome	9.7	SCN5A RYR2 KCNQ1 KCNH2
32	third-degree atrioventricular block	9.7	TTN SCN5A KCNJ2
33	pure autonomic failure	9.7	NPPA DBH
34	familial long qt syndrome	9.6	SCN5A KCNQ1 KCNJ2 KCNH2
35	long qt syndrome 6	9.6	SCN5A KCNQ1 KCNJ2 KCNH2
36	long qt syndrome 13	9.6	SCN5A KCNQ1 KCNJ2 KCNH2
37	brugada syndrome 4	9.6	SCN5A KCNQ1 KCNJ2 KCNH2
38	jervell and lange-nielsen syndrome 1	9.6	SCN5A KCNQ1 KCNJ2 KCNH2
39	wolff-parkinson-white syndrome	9.6	SCN5A KCNQ1 KCNJ2 KCNH2
40	hypokalemic periodic paralysis, type 1	9.6	SCN5A KCNJ2
41	neuromuscular disease	9.6	TTN SCN5A ACTN2
42	coronary artery anomaly	9.5	SCN5A RYR2 NPPA KCNH2
43	hypertrophic cardiomyopathy	9.5	TTN SCN5A RYR2 ACTN2
44	muscular disease	9.5	TTN SCN5A RYR2 ACTN2
45	atrial standstill 1	9.4	TTN SCN5A RYR2 NPPA
46	atrioventricular block	9.4	TTN SCN5A RYR2 KCNQ1 KCNH2
47	cardiac arrest	9.3	TTN SCN5A RYR2 KCNQ1 KCNH2
48	sick sinus syndrome	9.3	TTN SCN5A NPPA KCNJ2
49	long qt syndrome 5	9.3	SCN5A RYR2 KCNQ1 KCNJ2 KCNH2
50	sinoatrial node disease	9.3	SCN5A RYR2 KCNQ1 KCNJ2 KCNH2

Graphical network of the top 20 diseases related to Syncope:

Sources

Symptoms & Phenotypes for Syncope

MGI Mouse Phenotypes related to Syncope:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.81	DBH KCNH2 KCNJ2 KCNQ1 NPPA RYR2
2	growth/size/body region	MP:0005378	9.56	DBH KCNH2 KCNJ2 KCNQ1 RYR2 SCN5A
3	muscle	MP:0005369	9.17	KCNH2 KCNJ2 KCNQ1 NPPA RYR2 SCN5A

Sources

Drugs & Therapeutics for Syncope

Drugs for Syncope (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dopamine

Approved

Phase 4

51-61-6, 62-31-7

681

Fludrocortisone

Approved, Investigational

Phase 4

127-31-1

31378

Amlodipine

Approved

Phase 4

88150-42-9

2162

Losartan

Approved

Phase 4

114798-26-4

3961

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Bisoprolol

Approved

Phase 4

66722-44-9

2405

Interferon beta-1a

Approved, Investigational

Phase 4

145258-61-3

6438354

Interferon beta-1b

Approved

Phase 4

145155-23-3

Norgestimate

Approved, Investigational

Phase 4

35189-28-7

6540478

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Moxifloxacin

Approved, Investigational

Phase 4

151096-09-2, 354812-41-2

152946

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Ethinyl Estradiol

Approved

Phase 4

57-63-6

5991

Cefpirome

Approved

Phase 4

84957-29-9

5479539

Heparin

Approved, Investigational

Phase 4

9005-49-6

772 46507594

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Ramipril

Approved

Phase 4

87333-19-5

5362129

Guanfacine

Approved, Investigational

Phase 4

29110-47-2

3519

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Ticagrelor

Approved

Phase 4

274693-27-5

9871419

Pramipexole

Approved, Investigational

Phase 4

104632-26-0

59868 119570

Ropinirole

Approved, Investigational

Phase 4

91374-20-8, 91374-21-9

5095 497540

Metoprolol

Approved, Investigational

Phase 4

51384-51-1, 37350-58-6

4171

Diclofenac

Approved, Vet_approved

Phase 4

15307-86-5

3033

Sotalol

Approved

Phase 4

959-24-0, 3930-20-9

5253

Midodrine

Approved

Phase 4

42794-76-3, 133163-28-7

4195

Silodosin

Approved

Phase 4

160970-54-7

Tamsulosin

Approved, Investigational

Phase 4

106133-20-4

129211

Amiodarone

Approved, Investigational

Phase 4

1951-25-3

2157

Procainamide

Approved

Phase 4

51-06-9

4913

Adrenergic Agonists

Phase 4

Natriuretic Agents

Phase 4

Dopamine Agents

Phase 4

Antiparkinson Agents

Phase 4

diuretics

Phase 4

Protective Agents

Phase 4

Hormones

Phase 4

Sodium Chloride Symporter Inhibitors

Phase 4

calcium channel blockers

Phase 4

Contraceptive Agents

Phase 4

(T,G)-A-L

Phase 4

Fingolimod Hydrochloride

Phase 4

Interferon-beta

Phase 4

interferons

Phase 4

Glatiramer Acetate

Phase 4

147245-92-9

3081884

Adrenergic alpha-2 Receptor Agonists

Phase 4

Estradiol 17 beta-cypionate

Phase 4

Norgestimate, ethinyl estradiol drug combination

Phase 4

Contraceptives, Oral, Combined

Phase 4

Contraceptives, Oral

Phase 4

Interventional clinical trials:

(show top 50) (show all 365)

#	Name	Status	NCT ID	Phase	Drugs
1	Closed Loop Stimulation for Neuromediated Syncope	Unknown status	NCT01621464	Phase 4
2	Early Loop-Recorder in Suspected Arrhythmogenic Syncope	Completed	NCT00170261	Phase 4
3	ISSUE3: International Study on Syncope of Uncertain Etiology 3 Pacemaker Therapy for Patients With Asystolic Neurally-mediated Syncope	Completed	NCT00359203	Phase 4
4	A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II)	Completed	NCT00118482	Phase 4	fludrocortisone acetate
5	Syncope: Pacing or Recording in the Later Years (SPRITELY)	Completed	NCT01423994	Phase 4
6	Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis	Completed	NCT01133054	Phase 4
7	Propranolol for Syncope With Sympathoadrenal Imbalance	Completed	NCT00060866	Phase 4	Propranolol
8	The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension	Completed	NCT01964079	Phase 4	Amlodipine;Losartan
9	Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM)	Completed	NCT01074307	Phase 4	Low Dose Bisoprolol;High Dose Bisoprolol
10	A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)	Completed	NCT01623596	Phase 4	Fingolimod;Disease Modifying therapy
11	Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration	Completed	NCT00280514	Phase 4	cefpirome and moxifloxacin administration
12	Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy	Completed	NCT00916643	Phase 4
13	Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease	Completed	NCT02525081	Phase 4	Ramipril (ACE-inhibitor);placebo
14	Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine	Completed	NCT01146002	Phase 4	Guanfacine (sustained release)
15	Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease	Completed	NCT02383771	Phase 4	Ticagrelor;Aspirin + Ticagrelor;Control;Aspirin + Ticagrelor
16	An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose	Completed	NCT00344994	Phase 4	pramipexole
17	Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects	Recruiting	NCT02123056	Phase 4	Metoprolol;Matching Placebo
18	Effect of Pacemaker With Closed Loop Sensor on Quality of Life and Recurrence of Syncope in Patients With Neuromodulated Syncope Refractory to Medical Treatment: Randomized Double-blind Clinical Trial	Recruiting	NCT03876652	Phase 4
19	Effect of Pre-medication in Pain Measures on Office Hysteroscopy - Randomized Clinical Trial	Recruiting	NCT03506763	Phase 4	Placebo Oral + Placebo Oral;Diclofenac oral + Placebo Oral;Diclofenac oral + scopolamina oral
20	Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients.	Recruiting	NCT03686696	Phase 4	Beta blocker;ACEI;ARB
21	A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs	Recruiting	NCT02347111	Phase 4	Flecainide;Sotalol
22	Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4)	Active, not recruiting	NCT01456481	Phase 4	midodrine hydrochloride;matching placebo
23	Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study	Terminated	NCT00383799	Phase 4	iv Amiodarone;iv Procainamide
24	Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy	Terminated	NCT02369744	Phase 4	Silodosin;Tamsulosin
25	Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo	Unknown status	NCT02071459	Phase 2, Phase 3	L-Threo DOPS;placebo
26	Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome	Unknown status	NCT02823080	Phase 2, Phase 3	Cetrorelix
27	Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study About Lingdancao Granules in the Treatment of Seasonal Influenza	Unknown status	NCT02662426	Phase 3	Lingdancao granules;analogous oseltamivir phosphate capsule;Oseltamivir phosphate capsule;analogous Lingdancao granules
28	Randomized Controlled Trial on Discontinuation of Vasoactive Drugs in Patients With Hypotensive Reflex Syncope	Completed	NCT02137278	Phase 3	Vasoactive drug therapies
29	Comparison of Ivabradine and Beta-blockers Administration in the Treatment of Inappropriate Sinus Tachycardia	Completed	NCT01657136	Phase 3	Ivabradine;Beta blocker
30	CSP #563 - Prazosin and Combat Trauma PTSD (PACT)	Completed	NCT00532493	Phase 3	prazosin
31	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)	Completed	NCT00000464	Phase 3	amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
32	Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)	Completed	NCT01863186	Phase 3	Lofexidine HCl;Placebo;Open Label Lofexidine HCL
33	An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension	Completed	NCT00738062	Phase 3	Droxidopa;Placebo
34	Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH	Completed	NCT00782340	Phase 3	Placebo;Droxidopa
35	Antiarrhythmics Versus Implantable Defibrillators (AVID)	Completed	NCT00000531	Phase 3	amiodarone amiodarone;sotalol
36	A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease	Completed	NCT01176240	Phase 3	Droxidopa
37	Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH	Completed	NCT00633880	Phase 3	Placebo;Droxidopa
38	Comprehensive Approach to Lower Measured Blood Pressure (CALM-BP) - Results From a Randomized Controlled Trial	Completed	NCT00409149	Phase 3
39	A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy.	Completed	NCT00323973	Phase 3	Bisoprolol
40	Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients	Recruiting	NCT02809131	Phase 3	polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
41	Liposomal Bupivacaine To Control Post-Operative Pain Following Buccal Mucosal Graft Harvesting	Active, not recruiting	NCT03720223	Phase 3	Liposomal Bupivacaine
42	A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome	Not yet recruiting	NCT03365414	Phase 3	Normal Saline 0.9% Infusion Solution Bag
43	Intensive Blood Pressure Intervention in Stroke (IBIS) Trial	Not yet recruiting	NCT03585595	Phase 3
44	Benefit of Controlled Rehydration in Unexplained Syncope	Terminated	NCT00143754	Phase 3
45	BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator"	Terminated	NCT00927732	Phase 3	hydroquinidine;placebo (sugar)
46	Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL	Withdrawn	NCT01560091	Phase 3	silodosin;Tamsulosin
47	Second Study on Cardio-neuromodulation in Humans	Unknown status	NCT02954666	Phase 2
48	ECG Device for Long QT Syndrome Screening in Newborns	Unknown status	NCT02412709	Phase 2
49	A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST 6	Completed	NCT02500732	Phase 2	Atomoxetine;Placebo
50	A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope (POST 6)	Completed	NCT02874937	Phase 2	Atomoxetine;Matching Placebo

Search NIH Clinical Center for Syncope

Sources

Genetic Tests for Syncope

Genetic tests related to Syncope:

#	Genetic test	Affiliating Genes
1	Syncope ²⁹

Sources

Anatomical Context for Syncope

MalaCards organs/tissues related to Syncope:

⁴⁰

Testes, Heart, Brain, Skin, Lung, Prostate, Liver

Sources

Publications for Syncope

Articles related to Syncope:

(show top 50) (show all 15545)

#	Title	Authors	PMID	Year
1	Severe impaired blood pressure control caused by baroreflex failure as a late sequela of neck irradiation. ⁶¹	Piani F...Borghi C	31764585	2020
2	Ventricular conduction delay as marker of risk in Brugada Syndrome. Results from the analysis of clinical and electrocardiographic features of a large cohort of patients. ⁶¹	Giustetto C...Gaita F	31771792	2020
3	How to Prescribe Drugs With an Identified Proarrhythmic Liability. ⁶¹	Thind M...Turner JR	31743455	2020
4	Screening Pediatric Patients in New-Onset Syncope (SPINS) Study. ⁶¹	Gupta A...Gonzalez IE	31709814	2020
5	Web Exclusive. Annals Graphic Medicine - Dr. Mom: Syncope. ⁶¹	Farris GE	32016337	2020
6	Abolish the Tilt Table Test for the Workup of Syncope! ⁶¹	Kulkarni N...Levine BD	32011926	2020
7	Micturition Syncope: A Personal Experience With a Novel Explanation. ⁶¹	Auerbach AJ	31959316	2020
8	Left Atrial "Pinball" Thrombus Causing Recurrent Syncope. ⁶¹	Suraci N...Arenas I	32005792	2020
9	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. ⁶¹	Olanow CW...CTH-300 Study investigators	31818699	2020
10	Effect of Pregnancy in Arrhythmogenic Right Ventricular Cardiomyopathy. ⁶¹	Wu L...Yao Y	31836129	2020
11	Family history of associated disorders in patients with postural tachycardia syndrome. ⁶¹	Boris JR...Bernadzikowski T	32008600	2020
12	Medium-term results of cardioneuroablation for clinical bradyarrhythmias and vasovagal syncope: effects on QT interval and heart rate. ⁶¹	Aksu T...Gopinathannair R	32034611	2020
13	Pacing in vasovagal syncope: physiology, pacemaker sensors and recent clinical trials. Precise patient selection and measurable benefit. ⁶¹	Sutton R...de Lange FJ	32036025	2020
14	Impact of dual-chamber pacing with closed loop stimulation on quality of life in patients with recurrent reflex vasovagal syncope: results of the SPAIN study. ⁶¹	Baron-Esquivias G...Morillo CA	31713631	2020
15	Molecular genetic framework underlying pulmonary arterial hypertension. ⁶¹	Southgate L...Morrell NW	31406341	2020
16	Postural Tachycardia Syndrome and Neurally Mediated Syncope. ⁶¹	Cutsforth-Gregory JK	31996624	2020
17	The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. ⁶¹	Hernandez-Ojeda J...Brugada J	31864099	2020
18	Electrocardiogram Characteristics and Arrhythmic Events during Fever in Patients with Fever-Induced Brugada Syndrome. ⁶¹	Chen X...Zhang F	32015236	2020
19	Chest pain in Brugada syndrome prevalence, correlations and prognosis role. ⁶¹	Sebai F...Maury P	32031268	2020
20	SCN8A heterozygous variants are associated with anoxic-epileptic seizures. ⁶¹	Ranza E...Korff CM	32040247	2020
21	Parameters of Right Ventricular Function Reveal Ventricular-Vascular Mismatch as Determined by Right Ventricular Stroke Work versus Pulmonary Vascular Resistance in Children with Pulmonary Hypertension. ⁶¹	Di Maria MV...Friedberg MK	31836268	2020
22	Anomalous origin of the coronary artery coursing between the great vessels presenting with a cardiovascular event (J-CONOMALY Registry). ⁶¹	Nagashima K...Shoda M	31185091	2020
23	Drug-induced proarrhythmia: Discussion and considerations for clinical practice. ⁶¹	Klotzbaugh RJ...Turner JR	32015278	2020
24	Drug-induced proarrhythmia: Discussion and considerations for clinical practice. ⁶¹	Klotzbaugh RJ...Turner JR	31990841	2020
25	Risk Stratification of Older Adults Who Present to the Emergency Department With Syncope: The FAINT Score. ⁶¹	Probst MA...Sun BC	31668571	2020
26	Acute Myocarditis in Children: An Overview of Treatment and Recent Patents. ⁶¹	Fung RCM...Leung AKC	32013855	2020
27	Staged Combined Endovascular and Open Surgical Approach in a Patient with Takayasu's Arteritis. ⁶¹	Varzari A...Panneton JM	31629850	2020
28	Emergency department management of eating disorder complications in pediatric patients ⁶¹	Ernest S...Kuntz HM	31978295	2020
29	Cardiac Imaging in the Athlete: Shrinking the "Gray Zone". ⁶¹	Caruso MR...Martinez MW	32016641	2020
30	Differential diagnosis of vasovagal syncope and postural tachycardia syndrome in children. ⁶¹	Wang YY...Jin HF	32020440	2020
31	Convulsive Syncope Masquerading as Seizure After an Epidural Blood Patch. ⁶¹	D'Souza RS...Warner NS	31910260	2020
32	Ictal vasodepressive syncope in temporal lobe epilepsy. ⁶¹	Mastrangelo V...Tinuper P	31765979	2020
33	Epilepsy in the elderly: Unique challenges in an increasingly prevalent population. ⁶¹	Lezaic N...Keezer MR	31816480	2020
34	Memantine Induces Reflex Syncope in Elderly Patients With Dementia: Results From the Syncope and Dementia Study (SYD-Study). ⁶¹	Curcio F...Abete P	30872082	2020
35	Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. ⁶¹	Simon JA...Millheiser L	31735618	2020
36	Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. ⁶¹	Hashemi D...German Competence Network for Heart Failure	32003157	2020
37	Plasma-lactate levels in simulated seizures - An observational study. ⁶¹	Lou Isenberg A...Lindelof M	32004878	2020
38	Choosing wisely in emergency medicine: Early results and insights from the ACEP emergency quality network (E-QUAL). ⁶¹	Venkatesh AK...Schuur JD	32014376	2020
39	To STOPP or to START? Potentially inappropriate prescribing in older patients with falls and syncope. ⁶¹	de Ruiter SC...Jansen RWMM	31787149	2020
40	The Wide-Ranging Spectrum of Cough-Induced Complications and Patient Harm. ⁶¹	Schattner A	32007456	2020
41	Sources of Variability in Pediatric Head Computed Tomography Use Among Emergency Departments in New Jersey. ⁶¹	Holmes AM...Sheth S	31895199	2020
42	Syncope in Malaysian populations. ⁶¹	Sheldon RS	31925588	2020
43	Syncope in a young woman. ⁶¹	Mohanan Nair KK...Valaparambil A	31974258	2020
44	Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study. ⁶¹	Moon I...Cho GY	31929538	2020
45	Transient high-degree right bundle branch block masking the type 1 Brugada ECG pattern associated with possible transient early repolarization syndrome. ⁶¹	Perez-Riera AR...Nikus K	31343106	2020
46	Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension. ⁶¹	Luo Q...Yu B	31941943	2020
47	Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. ⁶¹	Pelliccia F...Olivotto I	31983465	2020
48	When Sinus Tachycardia Becomes Too Much: Negative Effects of Excessive Upright Tachycardia on Cardiac Output in Vasovagal Syncope, Postural Tachycardia Syndrome, and Inappropriate Sinus Tachycardia. ⁶¹	Stewart JM...Sutton R	31941353	2020
49	Comparison of trinitroglycerin and adenosine as provocative agents for head-up tilt test in patients with unexplained syncope: a semi-crossover randomized clinical trial with prospective follow-up. ⁶¹	Tajdini M...Bozorgi A	31907833	2020
50	Predictive Accuracy of Electrocardiographic Monitoring of Patients With Syncope in the Emergency Department: The SyMoNE Multicenter Study. ⁶¹	Solbiati M...Costantino G	31854141	2020

Sources

Genes for Syncope

Genes related to Syncope (0 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SLC6A2	Solute Carrier Family 6 Member 2	Protein Coding	24.5	GeneCards inferred via : Disorders Publications Summaries (show sections)
2	SCN5A	Sodium Voltage-Gated Channel Alpha Subunit 5	Protein Coding	24.33	GeneCards inferred via : Disorders Publications Variants (show sections)
3	KCNQ1	Potassium Voltage-Gated Channel Subfamily Q Member 1	Protein Coding	15.87	GeneCards inferred via : Disorders Publications (show sections)
4	KCNH2	Potassium Voltage-Gated Channel Subfamily H Member 2	Protein Coding	15.82	GeneCards inferred via : Disorders Publications (show sections)
5	ACTN2	Actinin Alpha 2	Protein Coding	14.94	GeneCards inferred via : Disorders Variants (show sections)
6	RYR2	Ryanodine Receptor 2	Protein Coding	14.94	GeneCards inferred via : Disorders Variants (show sections)
7	TTN	Titin	Protein Coding	14.94	GeneCards inferred via : Disorders Variants (show sections)
8	DBH	Dopamine Beta-Hydroxylase	Protein Coding	14.73	GeneCards inferred via : Disorders Publications (show sections)
9	NPPA	Natriuretic Peptide A	Protein Coding	14.73	GeneCards inferred via : Disorders Publications (show sections)
10	VVS	Syncope, Familial Vasovagal	Genetic Locus	7.76	GeneCards inferred via : Gene name (show sections)
11	KCNJ2	Potassium Inwardly Rectifying Channel Subfamily J Member 2	Protein Coding	7.43	GeneCards inferred via : Disorders (show sections)

Sources

Variations for Syncope

ClinVar genetic disease variations for Syncope:

⁶ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	SCN5A	NM_198056.2(SCN5A):c.1255C>T (p.Gln419Ter)	SNV	Likely pathogenic	374130	rs1057518916	3:38647525-38647525	3:38606034-38606034
2	ACTL6A	NM_004301.5(ACTL6A):c.1129C>T (p.Arg377Trp)	SNV	Likely pathogenic	549661	rs868064163	3:179304340-179304340	3:179586552-179586552
3	ACTN2	NM_001103.3(ACTN2):c.1040C>T (p.Thr347Met)	SNV	Conflicting interpretations of pathogenicity	178985	rs727504590	1:236902765-236902765	1:236739465-236739465
4	MEFV	NM_000243.2(MEFV):c.2084A>G (p.Lys695Arg)	SNV	Conflicting interpretations of pathogenicity	2547	rs104895094	16:3293403-3293403	16:3243403-3243403
5	KCNE3 , LIPT2	NM_005472.4(KCNE3):c.248G>A (p.Arg83His)	SNV	Conflicting interpretations of pathogenicity	5541	rs17215437	11:74168361-74168361	11:74457316-74457316
6	TTN	NM_001267550.2(TTN):c.11311+4088A>G	SNV	Conflicting interpretations of pathogenicity	47753	rs142304137	2:179613763-179613763	2:178749036-178749036
7	RYR2	NM_001035.3(RYR2):c.2026G>A (p.Glu676Lys)	SNV	Uncertain significance	689574		1:237659875-237659875	1:237496575-237496575

Sources

Expression for Syncope

Search GEO for disease gene expression data for Syncope.

Sources

Pathways for Syncope

Pathways related to Syncope according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	Transmission across Chemical Synapses ⁶⁵ Show member pathways Neuronal System ⁶⁵ Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell ⁶⁵	12.65	KCNQ1 KCNJ2 KCNH2 ACTN2
2	cGMP-PKG signaling pathway ³⁶ Show member pathways Adrenergic signaling in cardiomyocytes ³⁶	12.06	SCN5A RYR2 NPPA KCNQ1
3	Dopamine-DARPP32 Feedback onto cAMP Pathway ⁶³	11.99	KCNQ1 KCNJ2 KCNH2
4	Cardiac conduction ⁶⁵ Show member pathways Classical Kir channels ⁶⁵ Ion homeostasis ⁶⁵ Ion transport by P-type ATPases ⁶⁵ Muscle contraction ⁶⁵ Phase 1 - inactivation of fast Na+ channels ⁶⁵ Phase 3 - rapid repolarisation ⁶⁵ Phase 4 - resting membrane potential ⁶⁵ Physiological factors ⁶⁵ Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) ⁶⁵ Tandem pore domain halothane-inhibited K+ channel (THIK) ⁶⁵ Tandem pore domain potassium channels ⁶⁵ TWIK related potassium channel (TREK) ⁶⁵ TWIK-related alkaline pH activated K+ channel (TALK) ⁶⁵ TWIK-related spinal cord K+ channel (TRESK) ⁶⁵ TWIK-releated acid-sensitive K+ channel (TASK) ⁶⁵	11.95	TTN SCN5A RYR2 NPPA KCNQ1 KCNJ2
5	Potassium Channels ⁶⁵ Show member pathways HCN channels ⁶⁵ Voltage gated Potassium channels ⁶⁵	11.71	KCNQ1 KCNJ2 KCNH2
6	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.67	SCN5A RYR2 KCNQ1 KCNH2
7	Monoamine Transport ¹ Show member pathways Serotonin Transporter Activity ¹	11.11	SLC6A2 DBH
8	Antiarrhythmic Pathway, Pharmacodynamics ⁶⁰	11.1	SCN5A RYR2 KCNQ1 KCNJ2 KCNH2
9	Sympathetic Nerve Pathway (Neuroeffector Junction) ⁶⁰	10.79	SLC6A2 DBH
10	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁵	10.77	SLC6A2 DBH
11	TarBasePathway ¹	10.6	KCNQ1 KCNJ2

Sources

GO Terms for Syncope

Cellular components related to Syncope according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	intercalated disc	GO:0014704	9.37	SCN5A KCNJ2
2	voltage-gated potassium channel complex	GO:0008076	9.33	KCNQ1 KCNJ2 KCNH2
3	T-tubule	GO:0030315	9.32	SCN5A KCNJ2
4	smooth endoplasmic reticulum	GO:0005790	9.26	RYR2 KCNJ2
5	sarcomere	GO:0030017	9.13	TTN RYR2 ACTN2
6	Z disc	GO:0030018	8.92	TTN SCN5A RYR2 ACTN2

Biological processes related to Syncope according to GeneCards Suite gene sharing:

(show all 33)

#	Name	GO ID	Score	Top Affiliating Genes
1	ion transport	GO:0006811	9.93	SCN5A RYR2 KCNQ1 KCNJ2 KCNH2
2	transmembrane transport	GO:0055085	9.92	SLC6A2 SCN5A RYR2 KCNQ1 KCNH2
3	potassium ion transport	GO:0006813	9.81	KCNQ1 KCNJ2 KCNH2
4	potassium ion transmembrane transport	GO:0071805	9.81	KCNQ1 KCNJ2 KCNH2
5	regulation of ion transmembrane transport	GO:0034765	9.81	SCN5A KCNQ1 KCNJ2 KCNH2
6	positive regulation of heart rate	GO:0010460	9.67	RYR2 NPPA KCNQ1
7	potassium ion import across plasma membrane	GO:1990573	9.66	KCNJ2 KCNH2
8	sarcomere organization	GO:0045214	9.65	TTN ACTN2
9	muscle filament sliding	GO:0030049	9.65	TTN ACTN2
10	regulation of heart rate	GO:0002027	9.65	SCN5A RYR2
11	regulation of ventricular cardiac muscle cell membrane repolarization	GO:0060307	9.65	SCN5A KCNQ1 KCNH2
12	response to pain	GO:0048265	9.64	SLC6A2 DBH
13	membrane depolarization during action potential	GO:0086010	9.63	SCN5A KCNH2
14	positive regulation of potassium ion transmembrane transport	GO:1901381	9.63	KCNQ1 KCNJ2 KCNH2
15	cardiac muscle cell action potential involved in contraction	GO:0086002	9.62	SCN5A KCNJ2
16	response to muscle stretch	GO:0035994	9.62	RYR2 NPPA
17	cardiac conduction	GO:0061337	9.62	SCN5A KCNQ1 KCNJ2 KCNH2
18	potassium ion export across plasma membrane	GO:0097623	9.61	KCNQ1 KCNH2
19	regulation of cardiac muscle cell contraction	GO:0086004	9.61	SCN5A KCNJ2
20	regulation of membrane repolarization	GO:0060306	9.61	KCNQ1 KCNJ2 KCNH2
21	cellular response to epinephrine stimulus	GO:0071872	9.6	RYR2 KCNQ1
22	membrane repolarization during ventricular cardiac muscle cell action potential	GO:0098915	9.59	KCNQ1 KCNH2
23	membrane depolarization during cardiac muscle cell action potential	GO:0086012	9.58	SCN5A KCNJ2
24	membrane repolarization	GO:0086009	9.58	KCNQ1 KCNH2
25	membrane repolarization during cardiac muscle cell action potential	GO:0086013	9.58	KCNQ1 KCNJ2 KCNH2
26	positive regulation of cardiac muscle contraction	GO:0060452	9.57	NPPA KCNQ1
27	cardiac muscle hypertrophy	GO:0003300	9.56	TTN RYR2
28	atrial cardiac muscle cell action potential	GO:0086014	9.55	SCN5A KCNQ1
29	membrane repolarization during action potential	GO:0086011	9.54	KCNQ1 KCNJ2 KCNH2
30	regulation of heart rate by cardiac conduction	GO:0086091	9.46	SCN5A KCNQ1 KCNJ2 KCNH2
31	regulation of atrial cardiac muscle cell membrane repolarization	GO:0060372	9.43	SCN5A NPPA KCNQ1
32	ventricular cardiac muscle cell action potential	GO:0086005	9.26	SCN5A RYR2 KCNQ1 KCNH2
33	cardiac muscle contraction	GO:0060048	9.02	TTN SCN5A RYR2 KCNQ1 KCNH2

Molecular functions related to Syncope according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.91	TTN RYR2 KCNJ2 KCNH2 ACTN2
2	ion channel activity	GO:0005216	9.63	SCN5A RYR2 KCNH2
3	calmodulin binding	GO:0005516	9.56	TTN SCN5A RYR2 KCNQ1
4	structural constituent of muscle	GO:0008307	9.54	TTN ACTN2
5	phosphatidylinositol-4,5-bisphosphate binding	GO:0005546	9.54	KCNQ1 KCNJ2 ACTN2
6	delayed rectifier potassium channel activity	GO:0005251	9.52	KCNQ1 KCNH2
7	scaffold protein binding	GO:0097110	9.5	SCN5A KCNQ1 KCNH2
8	protein kinase A regulatory subunit binding	GO:0034237	9.49	RYR2 KCNQ1
9	inward rectifier potassium channel activity	GO:0005242	9.48	KCNJ2 KCNH2
10	ion channel binding	GO:0044325	9.46	SCN5A RYR2 KCNQ1 ACTN2
11	protein kinase A catalytic subunit binding	GO:0034236	9.43	RYR2 KCNQ1
12	voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	GO:1902282	9.4	KCNQ1 KCNH2
13	voltage-gated ion channel activity	GO:0005244	9.26	SCN5A KCNQ1 KCNJ2 KCNH2
14	voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	GO:0086008	8.8	KCNQ1 KCNJ2 KCNH2

Sources

Sources for Syncope

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia